Pharmacological evaluation of 5-{2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-1, 3-dihydro-benzimidazole-2-thione as a potential atypical antipsychotic agent

Pharmazie

Volumn 58, Issue 9, 2003, Pages 677-678

  Tomić, Mirko ^a   Kundakovic M ^a   Butorovic B ^a   Vasilev, V ^a   Dragovic, D ^b   Roglic G ^b   Ignjatovic D J ^c   Soskic V ^d   Kostic Rajacic S ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Institute for Chemistry   (Serbia)

^d PROTEOSYS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1H BENZOIMIDAZOL 5 YL)ETHYLDIPROPYLAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] 1,3 DIHYDROBENZIMIDAZOLE 2 THIONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; LIGAND; MEZULERGIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; RADIOLIGAND; ROXINDOLE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPIPERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZACOPRIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN SYNAPTOSOME; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ASSAY; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEROTONIN UPTAKE; STEREOTYPY; TECHNIQUE;

EID: 0141619390     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wiesel, F.-A.: Br. J. Psychiat. 164 (suppl. 23), 65 (1994)
2. Howard, H.: Exp. Opin. Ther. Patents. 7, 353 (1997)
3. Strange, P. G.: Pharmacol. Rev. 53, 119 (2001)
4. Meltzer, H. Y.: Neuropsychopharmacology 21 (suppl.2), 106 (1999)
5. Bantick, R. A.; Deakin, J. F.; Grasby, P. M. J.: Psychopharmacol. 15, 37 (2001)
6. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W. L.; O'Laughlin, I. A.; Meltzer, H. Y.: J. Neurochem. 76, 1521 (2001)
7. Artigas, F.; Romero, L.; de Montigny, C.; Blier, P.: TiNS 19, 378 (1996)
8. Newman-Tancredi, A.; Cussac, D.; Audinot, V.; Millan, M. J.: Naunyn Schmiedeberg's Arch. Pharmacol. 359, 447 (1999)
9. Dukić, S.; Kostić-Rajačić, S.; Dragović, D.; Šoškić, V.; Joksimović, J.: J. Pharm. Pharmacol. 49, 1036 (1997)
10. Roglić, G.; Dukić-Stefanović, S.; Andrić, D. ; Kostić-Rajačić, S; Šokić, V.: Pharmazie 56, 803 (2001)
11. Vogel, G. H.; Vogel, W. H. (Eds.): Drug Discovery and Evaluation - Pharmacological Assays. p. 269, Springer-Verlag, Berlin, Heidelberg, 1997
12. Holt, A; Sharman, D. F.; Baker, G. B.; Palcic, M. M.: Anal. Biochem. 244, 384 (1997)
13. Bruhwyler, J.; Chleide, E.; Mercier, M.: Neurosci. Biobehav. Rev. 14, 357 (1990)
14. Gattaz, W. F.; Schummer, B.; Behrens, S.: J. Neural. Transm. Gen. Sect. 96, 227 (1994)
15. Stockmeier, C. A.; Dicarlo, J. J.; Zhang, Y.; Thompson, P.; Meltzer, H. Y.: J. Pharmacol. Exp. Ther. 266, 1374 (1993)